Sonova Holding AG Announces Strong Half‑Year Results for 2025/26

Sonova Holding AG, a Swiss health‑care equipment company listed on the SIX Swiss Exchange, released an ad‑hoc announcement on 14 November 2025 reporting its first‑half financial performance for the fiscal year 2025/26. The company highlighted significant growth in both sales and earnings, expressed in local currencies, and noted that these results exceed market expectations.

Key Financial Highlights

  • Revenue growth: The company recorded a robust increase in revenue for the period, driven by its core business lines in hearing instruments and cochlear implants.
  • Profitability: Earnings also rose markedly, outperforming peers in the health‑care equipment sector.
  • Currency impact: The growth figures are presented in local currencies, underscoring strong performance across the company’s international markets.

Management Commentary

Eric Bernard, Chief Executive Officer of Sonova, remarked: “We are pleased to see strong momentum in our two largest businesses. In Hearing Instruments, we’ve continued to strengthen our portfolio with recent product launches that build on our leadership in AI and innovation.” The statement emphasized ongoing product development and a commitment to technological advancement.

Governance and Outlook

A separate communication issued on 13 November 2025 highlighted that the Swiss market ended the day on a weak note, with the SMI index falling 0.41 %. Within this context, Sonova’s results are positioned as a positive development for investors.

The company also noted that all attention is focused on the new management team, implying a transition phase that may influence future strategic decisions. No detailed forecast figures were disclosed in the announcement.

Market Context

Sonova’s performance comes at a time when the broader ENT devices market is projected to reach USD 37,580 million by 2032, growing at a CAGR of 6.08 % from 2025 to 2032 (source: SNS Insider). Additionally, the digital therapeutics segment for tinnitus is expected to grow to USD 4.64 billion by 2029 (source: TBRC Business Research). These trends suggest a favourable environment for Sonova’s product portfolio.

Stock Performance

As of 12 November 2025, Sonova’s closing share price was CHF 218.2, positioned below the 52‑week low of CHF 209.6 and within the 52‑week range of CHF 209.6–CHF 325.7. The company’s market capitalization stands at CHF 13.01 billion, with a price‑earnings ratio of 24.13.

The announcement underscores Sonova’s ability to deliver superior financial results while navigating a challenging market environment, reinforcing its standing as a leading provider of hearing solutions worldwide.